|
|
|
Dynavax Presents at the Wedbush Life Sciences Conference Dynavax Reports 2010 Second Quarter Financial Results Dynavax to Present at the Wedbush Life Sciences Conference Dynavax Promotes J. Tyler Martin, M.D. to President Dynavax Completes Enrollment and First Immunizations in Universal Flu Vaccine Study Dynavax Reports New Employment Inducement Awards Dynavax Appoints Daniel Kisner, M.D. to Board of Directors Dynavax Initiates First Human Trial in Universal Flu Vaccine Program Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine |
Our clinical-stage pipeline includes 3 product candidates for the prevention and treatment of infectious diseases. More...
|
Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.
Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Novartis, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.
Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
|
 |
